688621 阳光诺和
已收盘 09-11 15:00:01
资讯
新帖
简况
阳光诺和上半年净利转亏 2021上市募5亿国联民生保荐
中金财经 · 09-09
阳光诺和上半年净利转亏 2021上市募5亿国联民生保荐
阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发
中金财经 · 09-04
阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发
8月31日阳光诺和涨9.14%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 08-31
8月31日阳光诺和涨9.14%，融通健康产业灵活配置混合A/B基金重仓该股
阳光诺和（688621）2026年中报简析：净利润同比下降118.79%，三费占比上升明显
证券之星 · 08-30
阳光诺和（688621）2026年中报简析：净利润同比下降118.79%，三费占比上升明显
每周股票复盘：阳光诺和（688621）Q2净利下滑144.92%
证券之星 · 08-30
每周股票复盘：阳光诺和（688621）Q2净利下滑144.92%
阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发
中国财富通 · 08-29
阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发
阳光诺和（688621）发布关于使用部分募集资金向全资子公司增资以实施募投项目的公告，8月28日股价下跌3.66%
证券之星 · 08-28
阳光诺和（688621）发布关于使用部分募集资金向全资子公司增资以实施募投项目的公告，8月28日股价下跌3.66%
图解阳光诺和中报：第二季度单季净利润同比下降144.92%
证券之星 · 08-28
图解阳光诺和中报：第二季度单季净利润同比下降144.92%
阳光诺和(688621)6月30日股东户数0.77万户，较上期减少3.28%
证券之星 · 08-28
阳光诺和(688621)6月30日股东户数0.77万户，较上期减少3.28%
每周股票复盘：阳光诺和（688621）实控人转让5%股份完成过户
证券之星 · 08-16
每周股票复盘：阳光诺和（688621）实控人转让5%股份完成过户
阳光诺和半年报预亏警示：仿创转型下三重经营风险凸显
新浪证券 · 08-14
阳光诺和半年报预亏警示：仿创转型下三重经营风险凸显
股市必读：阳光诺和新发布《关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告》
证券之星 · 08-14
股市必读：阳光诺和新发布《关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告》
阳光诺和（688621）披露2025年限制性股票激励计划首次授予部分第一个归属期归属结果公告，8月12日股价上涨3.74%
证券之星 · 08-12
阳光诺和（688621）披露2025年限制性股票激励计划首次授予部分第一个归属期归属结果公告，8月12日股价上涨3.74%
8月7日阳光诺和涨7.31%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 08-07
8月7日阳光诺和涨7.31%，融通健康产业灵活配置混合A/B基金重仓该股
8月3日阳光诺和涨5.04%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 08-03
8月3日阳光诺和涨5.04%，融通健康产业灵活配置混合A/B基金重仓该股
每周股票复盘：阳光诺和（688621）拟投1000万元加码纳米药物布局
证券之星 · 08-02
每周股票复盘：阳光诺和（688621）拟投1000万元加码纳米药物布局
阳光诺和获得发明专利授权：“鲁拉西酮冻干口崩片及其制备方法与应用”
证券之星 · 08-01
阳光诺和获得发明专利授权：“鲁拉西酮冻干口崩片及其制备方法与应用”
阳光诺和(688621.SH)拟1000万元受让弼领生物部分股权
智通财经 · 07-28
阳光诺和(688621.SH)拟1000万元受让弼领生物部分股权
阳光诺和(688621.SH)：STC009注射液获得药物临床试验批准通知书
智通财经 · 07-28
阳光诺和(688621.SH)：STC009注射液获得药物临床试验批准通知书
阳光诺和：子公司STC009注射液获临床试验批准
格隆汇 · 07-28
阳光诺和：子公司STC009注射液获临床试验批准
加载更多
公司概况
公司名称：
北京阳光诺和药物研究股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-06-21
主营业务：
北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是药物发现、药理药效、药学研究、临床研究、生物分析。公司先后获评国家第五批专精特新“小巨人”企业、北京市高新技术企业、北京市知识产权试点单位、北京市专精特新中小企业等多项资质与荣誉。
发行价格：
26.89
{"stockData":{"symbol":"688621","market":"SH","secType":"STK","nameCN":"阳光诺和","latestPrice":68.56,"timestamp":1789110001000,"preClose":69.6,"halted":0,"volume":2079326,"delay":0,"changeRate":-0.0149,"floatShares":112000000,"shares":112000000,"eps":0.4432,"marketStatus":"已收盘","change":-1.04,"latestTime":"09-11 15:00:01","open":69.2,"high":69.75,"low":66.53,"amount":141000000,"amplitude":0.0463,"askPrice":68.57,"askSize":3,"bidPrice":68.56,"bidSize":82,"shortable":0,"etf":0,"ttmEps":0.4432,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":69.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":76.56,"lowLimit":62.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":112000000,"isCdr":false,"pbRate":6.39,"roa":"--","peRate":154.693141,"roe":"--","epsLYR":1.86,"committee":0.800623,"marketValue":7679000000,"turnoverRate":0.0186,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","afterMarket":{"amount":0,"volume":0,"close":68.56,"buyVolume":0,"sellVolume":0,"time":1789112037746,"indexStatus":"已收盘 09-11 15:30:00","preClose":69.6},"floatMarketCap":7679000000},"requestUrl":"/m/hq/s/688621","defaultTab":"news","newsList":[{"id":"2666538585","title":"阳光诺和上半年净利转亏 2021上市募5亿国联民生保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538585","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666538585?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:12","pubTimestamp":1788941523,"startTime":"0","endTime":"0","summary":"中国经济网北京9月9日讯 阳光诺和 近期发布2026年半年度报告。2026年上半年，公司实现营业收入4.26亿元，同比下滑27.81%；归属于上市公司股东的净利润-2440.00万元，去年同期为1.30亿元；归属于上市公司股东的扣除非经常性损益的净利润-2507.03万元，去年同期为1.20亿元；经营活动产生的现金流量净额为-5153.21万元。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/09/20260909513461.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/09/20260909513461.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260909/32364751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0276","01456","688621","BK1564","601456","BK0216","BK1147","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238341","title":"阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238341","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238341?lang=zh_cn&edition=full","pubTime":"2026-09-04 10:12","pubTimestamp":1788487931,"startTime":"0","endTime":"0","summary":"8月28日，阳光诺和(688621)披露2026年半年报，报告期内，公司实现营收4.26亿元。公司战略转型成效渐显：自研1类创新药STC007(瘙痒)完成对外授权，STC008(肿瘤恶液质)临床推进，多个多肽、小核酸、CAR-T管线进入临床阶段；研发投入占营收的比例升至20.54%，技术平台持续升级。公司坚持“CRO服务+自主新药”双轮驱动，以技术转化沉淀长期价值，创新储备与权益分成模式逐渐构筑起未来增长基石。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260904/32359746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663075957","title":"8月31日阳光诺和涨9.14%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663075957","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663075957?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:39","pubTimestamp":1788165589,"startTime":"0","endTime":"0","summary":"证券之星消息，8月31日阳光诺和涨9.14%，收盘报68.87元，换手率5.9%，成交量6.61万手，成交额4.53亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100022327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663904817","title":"阳光诺和（688621）2026年中报简析：净利润同比下降118.79%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663904817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663904817?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:18","pubTimestamp":1788041889,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期阳光诺和发布2026年中报。截至本报告期末，公司营业总收入4.26亿元，同比下降27.81%，归母净利润-2440.0万元，同比下降118.79%。本报告期阳光诺和三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达96.28%。去年的净利率为17.22%，算上全部成本后，公司产品或服务的附加值高。本文数据来源于阳光诺和2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010475","title":"每周股票复盘：阳光诺和（688621）Q2净利下滑144.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010475","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010475?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:48","pubTimestamp":1788032891,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，阳光诺和报收于63.1元，较上周的66.01元下跌4.41%。本周，阳光诺和8月24日盘中最高价报68.5元。阳光诺和当前最新总市值70.67亿元，在医疗服务板块市值排名27/51，在两市A股市值排名2429/5211。本周关注点来自业绩披露要点：2026年第二季度归母净利润为-4503.11万元，同比下降144.92%。股本股东变化截至2026年6月30日，阳光诺和股东户数为7726.0户，较3月31日减少262.0户，减幅为3.28%。该项计提减少合并报表利润总额约6505.21万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663111670","title":"阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2663111670","media":"中国财富通","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663111670?lang=zh_cn&edition=full","pubTime":"2026-08-29 10:55","pubTimestamp":1787972108,"startTime":"0","endTime":"0","summary":"8月28日，阳光诺和（688621）披露2026年半年报，报告期内，公司实现营收4.26亿元。公司战略转型成效渐显：自研1类创新药STC007（瘙痒）完成对外授权，STC008（肿瘤恶液质）临床推进，多个多肽、小核酸、CAR-T管线进入临床阶段；研发投入占营收的比例升至20.54%，技术平台持续升级。公司坚持“CRO服务+自主新药”双轮驱动，以技术转化沉淀长期价值，创新储备与权益分成模式逐渐构筑起未来增长基石。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=q1xvD6GfAdk%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099997","title":"阳光诺和（688621）发布关于使用部分募集资金向全资子公司增资以实施募投项目的公告，8月28日股价下跌3.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099997","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662099997?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:11","pubTimestamp":1787926301,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，阳光诺和报收于63.1元，较前一交易日下跌3.66%，最新总市值为70.67亿元。近日，北京阳光诺和药物研究股份有限公司披露《关于使用部分募集资金向全资子公司增资以实施募投项目的公告》。公司于2026年8月28日召开第三届董事会第三次会议，审议通过使用部分募集资金向全资子公司成都诺和晟泰生物科技有限公司增资9,000.00万元，用于实施‘创新药研发项目’。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800053970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061943","title":"图解阳光诺和中报：第二季度单季净利润同比下降144.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061943","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662061943?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:20","pubTimestamp":1787912434,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和2026年中报显示，上半年度公司主营收入4.26亿元，同比下降27.81%；归母净利润-2440.0万元，同比下降118.79%；扣非净利润-2507.03万元，同比下降120.95%；其中2026年第二季度，公司单季度主营收入2.29亿元，同比下降36.28%；单季度归母净利润-4503.11万元，同比下降144.92%；单季度扣非净利润-4442.46万元，同比下降144.66%；负债率46.3%，投资收益51.63万元，财务费用677.39万元，毛利率49.19%。财报数据概要请见下图:本文数据来源于阳光诺和2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800043243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662663690","title":"阳光诺和(688621)6月30日股东户数0.77万户，较上期减少3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662663690","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662663690?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:42","pubTimestamp":1787910177,"startTime":"0","endTime":"0","summary":"证券之星消息，近日阳光诺和披露，截至2026年6月30日公司股东户数为7726.0户，较3月31日减少262.0户，减幅为3.28%。在医疗服务行业个股中，阳光诺和股东户数低于行业平均水平，截至6月30日，医疗服务行业平均股东户数为4.76万户。从股价来看，2026年3月31日至2026年6月30日，阳光诺和区间跌幅为14.14%，在此期间股东户数减少262.0户，减幅为3.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800040833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176847","title":"每周股票复盘：阳光诺和（688621）实控人转让5%股份完成过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176847","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176847?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:34","pubTimestamp":1786818852,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，阳光诺和报收于65.59元，较上周的64.88元上涨1.09%。本周，阳光诺和8月13日盘中最高价报68.38元。本周关注点公司公告汇总：实控人转让5.00%股份已完成过户登记。公司已收到股权激励对象缴纳的认购款共计23,173,586.04元，并取得验资报告及过户登记确认书。转让后，利虔持股比例由27.59%降至22.59%，受让方持股5.00%。受让方承诺12个月内不减持所获股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659197166","title":"阳光诺和半年报预亏警示：仿创转型下三重经营风险凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2659197166","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659197166?lang=zh_cn&edition=full","pubTime":"2026-08-14 12:00","pubTimestamp":1786680000,"startTime":"0","endTime":"0","summary":"2024 至 2025 年，仿制药药学服务营收从 5.59 亿元降至 3.38 亿元，降幅近 40%，毛利率自 61.37% 腰斩至 32.84%，营收占比大幅缩水。尽管 2025 年创新药研发服务收入 2.48 亿元、毛利率 96.87%，全年新签订单同比增长 13.10%，但新兴业务仍处在培育阶段，营收体量有限，短期内无法填补传统业务收缩形成的收入缺口，主业青黄不接的局面难以快速改善。整体来看，阳光诺和转型创新药赛道贴合行业长期发展方向，但当下同时承受盈利结构脆弱、主业衔接断层、大额资本投入三重压力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-08-14/doc-ininhaiv9472328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659049169","title":"股市必读：阳光诺和新发布《关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659049169","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659049169?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:39","pubTimestamp":1786642749,"startTime":"0","endTime":"0","summary":"公司公告汇总关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告北京阳光诺和药物研究股份有限公司已完成2025年限制性股票激励计划首次授予部分第一个归属期的股份归属登记，本次归属股票数量为1,032,691股，来源为公司从二级市场回购的A股普通股股票，共有113名激励对象参与归属。本次转让已于2026年8月11日完成过户登记，股份性质为无限售流通股。转让后，利虔持股比例由27.59%降至22.59%，受让方持股5.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197378","title":"阳光诺和（688621）披露2025年限制性股票激励计划首次授予部分第一个归属期归属结果公告，8月12日股价上涨3.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197378","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658197378?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:33","pubTimestamp":1786527206,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，阳光诺和报收于66.25元，较前一交易日上涨3.74%，最新总市值为74.2亿元。近日，北京阳光诺和药物研究股份有限公司披露《关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告》。公告显示，公司已完成2025年限制性股票激励计划首次授予部分第一个归属期的股份归属登记，本次归属股票数量为1,032,691股，来源为公司从二级市场回购的A股普通股股票，共有113名激励对象参与归属。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200030013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163766","title":"8月7日阳光诺和涨7.31%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657163766?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:43","pubTimestamp":1786092215,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日阳光诺和涨7.31%创60日新高，收盘报64.88元，换手率3.75%，成交量4.2万手，成交额2.66亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656324966","title":"8月3日阳光诺和涨5.04%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656324966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656324966?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:42","pubTimestamp":1785746544,"startTime":"0","endTime":"0","summary":"证券之星消息，8月3日阳光诺和涨5.04%，收盘报60.03元，换手率2.64%，成交量2.96万手，成交额1.75亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300021640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656316026","title":"每周股票复盘：阳光诺和（688621）拟投1000万元加码纳米药物布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656316026?lang=zh_cn&edition=full","pubTime":"2026-08-02 02:44","pubTimestamp":1785609851,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，阳光诺和报收于57.15元，较上周的55.22元上涨3.5%。本周，阳光诺和7月28日盘中最高价报59.59元。本周关注点公司公告汇总：阳光诺和以1000万元增资上海弼领生物，持股比例升至2.2671%。公司公告汇总北京阳光诺和药物研究股份有限公司以自有资金1,000.00万元受让杭州交子茶业有限公司持有的上海弼领生物技术有限公司4.0865万元注册资本，对应持股比例由2.0435%增至2.2671%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656939623","title":"阳光诺和获得发明专利授权：“鲁拉西酮冻干口崩片及其制备方法与应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2656939623","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656939623?lang=zh_cn&edition=full","pubTime":"2026-08-01 03:38","pubTimestamp":1785526705,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示阳光诺和新获得一项发明专利授权，专利名为“鲁拉西酮冻干口崩片及其制备方法与应用”，专利申请号为CN202111180979.1，授权日为2026年7月31日。今年以来阳光诺和新获得专利授权4个，较去年同期减少了33.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100003600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002197","title":"阳光诺和(688621.SH)拟1000万元受让弼领生物部分股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002197","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654002197?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:48","pubTimestamp":1785242916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和 发布公告，为推进在新型纳米偶联药物和精准纳米递送领域的整体战略布局，公司拟以现金1000万元受让杭州交子茶业有限公司持有的上海弼领生物技术有限公司注册资本4.0865万元。本次股权转让前公司持有弼领生物2.0435%的股权，转让完成后将持有弼领生物2.2671%的股权。弼领生物已提交十余项发明专利，其中多项已在中、美、欧、日等地获权;多个候选药物正加速推进临床，未来将持续刷新治疗标准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654026690","title":"阳光诺和(688621.SH)：STC009注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2654026690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654026690?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:45","pubTimestamp":1785242733,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司全资子公司成都诺和晟泰生物科技有限公司(简称“诺和晟泰”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目STC009注射液的临床试验申请获得批准。STC009注射液拟申报适应症为继发性甲状旁腺功能亢进症(SHPT)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","BMED","BK0216","IBBJ","PSYK","688621","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001802","title":"阳光诺和：子公司STC009注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001802","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654001802?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:45","pubTimestamp":1785239124,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789288032763,"stockEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":0.0349},{"period":"3month","weight":0.3166},{"period":"6month","weight":0.1148},{"period":"1year","weight":-0.1095},{"period":"ytd","weight":0.1071}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京阳光诺和药物研究股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"7726人(较上一季度减少3.28%)","perCapita":"14496股","listingDate":"2021-06-21","address":"北京市昌平区科技园区双营西路79号院7号楼一层","registeredCapital":"11200万元","survey":" 北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是药物发现、药理药效、药学研究、临床研究、生物分析。公司先后获评国家第五批专精特新“小巨人”企业、北京市高新技术企业、北京市知识产权试点单位、北京市专精特新中小企业等多项资质与荣誉。","listedPrice":26.89},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阳光诺和,688621,阳光诺和股票,阳光诺和股票老虎,阳光诺和股票老虎国际,阳光诺和行情,阳光诺和股票行情,阳光诺和股价,阳光诺和股市,阳光诺和股票价格,阳光诺和股票交易,阳光诺和股票购买,阳光诺和股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}